It may have listings in Hong Kong and Shanghai, but cancer drug maker BeiGene Ltd. (BGNE.US; 6160.HK; 668235.SH) is making it clear it wants to keep its original listing in the U.S. that is currently under threat due to U.S.-China tensions.
作者阳歌，本文仅代表作者个人观点
您已阅读3%（256字），剩余97%（7786字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。